Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: chronic obstructive pulmonary disease (COPD)
Draft recommendations posted for stakeholder feedback: July 29, 2021
End of feedback period: August 13, 2021